MAY 28, 2020 8:30 AM PDT

Trial for Arthritis Drug with Remdesivir to Beat COVID-19

WRITTEN BY: Annie Lennon

Montefiore Health System and Albert Einstein College of Medicine in New York have teamed up to see how well remdesivir, a drug already approved for COVID-19 treatment, works with an anti-inflammatory drug known as baricitinib against the virus. 

Preliminary results from clinical trials with remdesivir have shown that the drug is able to reduce recovery times from COVID-19 from 15 days to 11 days. Of the 1,063 patients involved in that trial, 91 were from either Montefiore or Einstein hospitals. 

Expanding on these results, doctors and researchers between these hospitals are studying whether remdesivir in combination with baricitinib can yield even better results. Baricitinib is so far known for reducing inflammation linked to rheumatoid arthritis. The researchers' goal is to determine whether the drug, when taken with remdesivir, reduces or prevents cytokine storms (excessive inflammation), which can overwhelm a patient's lungs and other organs, eventually leading to death. 

To do so, they are conducting a placebo-controlled, double-blind, randomized trial for the drug combination. Patients selected for the trial should be hospitalized with a confirmed COVID-19 diagnosis and lung complications, including abnormal chest X-rays, pneumonia, and need of a mechanical ventilator to breathe. While all patients will receive remdesivir intravenously for up to 10 days, half of the patients will be given baricitinib by mouth, and the other half an identical placebo, for up to two weeks. 

"What concerns us is that in some people the immune response to coronavirus can be more deadly than the infection itself, and there is no known treatment for this yet," says Barry Zingman, one of the study's authors also involved in the original remdesivir study. 

"Including baricitinib in our trial may reduce COVID-19-related inflammation and combining baricitinib with remdesivir may yield an even more effective treatment option for people most severely affected by this illness." 


Sources: Science Daily, News Medical

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
MAY 14, 2020
Immunology
MAY 14, 2020
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
Antibodies are a powerful countermeasure against COVID-19. Not only can they relieve symptoms in patients experiencing s ...
MAY 17, 2020
Cell & Molecular Biology
MAY 17, 2020
Potential Treatment for Brain and Spinal Cord Injury is IDed
Treatment options are limited for people that have suffered swelling-inducing injuries to their brain and spinal cord. N ...
MAY 25, 2020
Drug Discovery & Development
MAY 25, 2020
Hydrochloroquine Increases Risk of Death by COVID-19
Researchers have found that hydroxychloroquine is not an effective treatment for COVID-19. Their study found that it lea ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Drug Targets Off Episodes of Parkinson
A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred ...
MAY 26, 2020
Drug Discovery & Development
MAY 26, 2020
Eliminating Drug Side-Effects
Can we live in a world that completely eliminates side-effects from therapeutics? Well, scientists from Hong Kong Baptis ...
JUN 26, 2020
Cancer
JUN 26, 2020
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immatu ...
Loading Comments...